Metropolis Healthcare, led by Ameera Shah, has launched the TruHealth Cancer Screen 360—an integrated cancer screening panel developed to address the rising burden of cancer in India. The announcement positions the company’s preventive oncology offering as a first-of-its-kind in the Indian diagnostics sector.
The TruHealth Cancer Screen 360 introduces scientifically curated Male and Female Profiles, developed to provide early diagnostic insights to clinicians and individuals. According to Metropolis Healthcare, the launch aims to enhance access to specialised cancer diagnostics and improve affordability and inclusion in cancer screening services.
The initiative comes against the backdrop of cancer remaining a key public health challenge in India. As per the Global Cancer Observatory (GLOBOCAN) 2022, India ranks third in cancer incidence, second in cancer-related mortality in the South-East Asia region, and 121st globally in terms of crude rates. Screening coverage in India continues to remain under 1 per cent for common cancers such as cervical, breast, and oral—significantly below the World Health Organization’s 70 per cent screening target for cervical cancer.
The TruHealth Cancer Screen 360 offers a multi-layered screening approach that includes tumour markers, hereditary cancer risk analysis, and gender-specific assessments. These include prostate-specific antigen (PSA) for prostate cancer in men and HPV self-sampling for cervical cancer in women. The test panel has been designed to enable early detection of commonly occurring cancers such as breast, cervical, ovarian, liver, lung, prostate, colorectal, and thyroid cancers.
Commenting on the development, Surendran Chemmenkottil, CEO of Metropolis Healthcare, said, “The introduction of TruHealth Cancer Screen 360 Male and Female Profiles reflects our unwavering commitment to strengthening preventive healthcare in India. By equipping individuals with timely and reliable diagnostic tools, we aim to empower them to take charge of their health. Early detection is key to reducing the burden of late-stage cancer, improving outcomes, and saving lives. This initiative is also aligned with our strategic focus on expanding Metropolis’ footprint in oncology diagnostics—an increasingly critical domain in healthcare. We remain committed to making advanced diagnostics accessible and affordable across both urban and non-urban areas.”
GLOBOCAN’s findings also highlight a trend of earlier cancer onset, especially in urban populations. The rising incidence of breast, cervical, and ovarian cancers in women and lung and prostate cancers in men often results in late-stage diagnoses, which can reduce treatment effectiveness and patient outcomes.
Dr Kirti Chadha, Senior Oncopathologist and Chief Scientific and Innovation Officer at Metropolis Healthcare, said, “With the growing incidence of gender-specific cancers such as breast, cervical, and prostate, there is an urgent need to integrate targeted cancer screening into routine health check-ups. The TruHealth Cancer Screen 360 has been developed as an evidence-based, comprehensive tool that goes beyond general wellness testing. By incorporating a broad spectrum of biomarkers and hereditary risk indicators, it facilitates early identification of cancer risks—even before symptoms appear. This approach enhances clinical decision-making and provides individuals with actionable insights, helping bridge the gap between symptomless disease progression and timely medical intervention.”
The screening tool offers three-tiered diagnostics, combining tumour marker testing, hereditary risk profiling across more than 25 cancer types, and organ-specific assessments. It includes hereditary cancer screening through a NextGen Panel that analyses 317 genes. The female profile also offers HPV self-sampling kits, as recommended by the WHO, to increase the ease and frequency of cervical cancer screening. Free genetic counselling is included to help individuals understand their results and take informed next steps.
The TruHealth Cancer Screen 360 is being offered at an introductory price that is lower than the combined cost of individual tests. With a diagnostic portfolio of more than 4,000 tests and profiles, Metropolis Healthcare aims to expand the role of preventive screening in India through this launch.
